Inflammacheck®
Breath Test for Early Lung Cancer Screening
A simple, non-invasive device delivering instant results at the Point of Care to help detect lung cancer when it is most treatable.
Screening for lung cancer,
made simple
With Inflammacheck®, advanced factory calibrated sensors monitor respiratory condition and inflammation through normal, tidal breathing. With our light-weight and simple design, tests can be carried out quickly and easily on all patients, regardless of the severity of their disease.
Early detection through natural breathing
Inflammacheck makes lung cancer screening comfortable and straightforward. Patients only need to breathe naturally into the device—no forced manoeuvres, invasive procedures, or complex instructions. The process is gentle and can be performed by virtually anyone.
For healthcare staff, operation requires no specialist training: the device runs a fully automated cycle, ensuring standardised test execution. This simplicity enables lung cancer screening to be deployed widely in primary care and community settings, lowering barriers to early diagnosis.
Early detection through natural breathing
Inflammacheck makes lung cancer screening comfortable and straightforward. Patients only need to breathe naturally into the device—no forced manoeuvres, invasive procedures, or complex instructions. The process is gentle and can be performed by virtually anyone.
For healthcare staff, operation requires no specialist training: the device runs a fully automated cycle, ensuring standardised test execution. This simplicity enables lung cancer screening to be deployed widely in primary care and community settings, lowering barriers to early diagnosis.
From breath sample to cancer risk result in minutes
Inflammacheck® is the only device to combine exhaled breath condensate analysis with gas-phase measurement in one seamless process. Its disposable cartridge captures biomarkers such as hydrogen peroxide, strongly associated with lung cancer, while simultaneously logging supporting breath parameters.
The integrated, automated assay eliminates laboratory handling and ensures a consistent test procedure. This innovation brings high-value diagnostic insight directly to the Point of Care, enabling efficient, affordable screening that can identify patients at risk of lung cancer much earlier.
Every breath tells the story of lung health
From breath sample to cancer risk result in minutes
Inflammacheck® is the only device to combine exhaled breath condensate analysis with gas-phase measurement in one seamless process. Its disposable cartridge captures biomarkers such as hydrogen peroxide, strongly associated with lung cancer, while simultaneously logging supporting breath parameters.
The integrated, automated assay eliminates laboratory handling and ensures a consistent test procedure. This innovation brings high-value diagnostic insight directly to the Point of Care, enabling efficient, affordable screening that can identify patients at risk of lung cancer much earlier.
Every breath tells the story
of lung health
Each Inflammacheck test produces a comprehensive “Breath Print” — hundreds of data points capturing both biomarker levels and breathing dynamics. By analysing full curve sets rather than single values, the device reveals subtle patterns that strengthen detection accuracy. For lung cancer screening, this richness provides a sharper distinction between healthy individuals and those showing early signs of disease. The Breath Print creates a reliable foundation for risk assessment, making Inflammacheck a valuable tool in the pathway to early intervention.
Every breath tells the story
of lung health
Each Inflammacheck test produces a comprehensive “Breath Print” — hundreds of data points capturing both biomarker levels and breathing dynamics. By analysing full curve sets rather than single values, the device reveals subtle patterns that strengthen detection accuracy. For lung cancer screening, this richness provides a sharper distinction between healthy individuals and those showing early signs of disease. The Breath Print creates a reliable foundation for risk assessment, making Inflammacheck a valuable tool in the pathway to early intervention.
AI transforming breath into early cancer signals
Inflammacheck® is fully automatic and requires no specialist training
At the point of care, patients simply breathe normally for 1–3 minutes; a clear result follows in under two minutes.
Non-invasive and fast, it delivers accurate, actionable “Breath Print” insights — conducting a full test cycle and establishing lung-cancer risk in less than five minutes, to streamline routine consultations.